We speak with Azitra’s COO Travis Whitfill about EGFRi associated rash and the rationale behind ATR-04.
$AZTR
#Azitra #NethertonSyndrome #RareDisease

#QNRX just got the green light from the FDA to launch its second pivotal trial of QRX003 for Netherton Syndrome.
#QuoinPharma #NethertonSyndrome.

prismmarketview.com/quoin-pharma...

Quoin Pharmaceuticals Reports Strong Q1 Progress with Breakthroughs in Netherton Syndrome Treatment The late-stage specialty pharmaceutical company developing treatments for rare and orphan diseases Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), announced a robust

#QNRX Reports Strong Q1 Progress with Breakthroughs in Netherton Syndrome Treatment
#NethertonSyndrome #QuoinPharmaceuticals
prismmarketview.com/quoin-pharma...